They were randomly assigned into two groups. Eleven patients were treated this website by two injections of BT at four weeks interval.

In another group, EO was injected 3 times with two weeks intervals. All patients were followed by achalasia symptom score (ASS) and timed barium esophagram (TBE). We defined good response as decrease in ASS (≤4), and reduction of height and volume of barium in TBE > 80% of baseline at 1.5 months after last injection. Relapse was defined as increase in ASS (>4) after initial good response. Results: Mean age of patients was 63.14 ± 13.2 years (Min: 26, Max: 81). All patients in EO group and ten patients in BT group revealed good initial response Five patients in EO and four in BT groups, who had relapsed, were treated by re-injection. XL765 The mean duration of follow up was 27.38 months Finally, in BT group, six patients had good response (ASS ≤ 4) and five had poor response, but in EO group good responses were nine and only one patient had a poor response.(P value: 0.049) Conclusion: This study revealed that both BT and EO are effective

in the treatment of IA, but in long term follow up more patients in EO group remained in remission. Moreover, the cost of BT is approximately 20 times more than EO. We suggest the use of EO in selected patients with IA. Key Word(s): 1. Achalasia; 2. Botulinum Toxin; 3. Ethanolamine oleate; Presenting Author: FANDONG MENG Additional Authors: WENYAN LI, QIAOZHI ZHOU, YONGDONG WU, MING JI, SHUTIAN ZHANG Corresponding Author: FANDONG MENG Affiliations: Capital Medical University, Beijing Friendship Hospital Objective: Achalasia is divided into 3 subtypes 上海皓元医药股份有限公司 using the Chicago classification for high-resolution manometry (HRM). Aim of this study was to apply the achalasia subtypes classification to a retrospective cohort of patients referred for esophageal manometry and to compare clinical and manometric characteristics between the 3 subtypes. Methods: Patients referred for esophageal manometry and diagnosed with achalasia on HRM

were retrospectively identified in Beijing friendship hospital. Only untreated patients before HRM were included in the retrospective study. Symptoms (dysphagia, chest pain, regurgitation) were collected at the time of HRM. Three achalasia subtypes were determined based on the Chicago classification. Clinical characteristics and manometric parameters were compared. Results: From January 2012 to March 2013 achalasia was diagnosed in 33 patients, 25 were untreated achalasia. 20% of patients were classified as type I, 60% as type II and 20% as type III. 100% of patients complained of dysphagia, 27% of type II patients presented chest pain. 53% of type I patients presented regurgitations compared to 20% of type II and 48% of type III (p = 0.36). Dilatation of esophagus was shown in 60% of type I patents, 73% for type II and 20% for type III.